Business Wire

SEOUL-SEMICONDUCTOR

9.11.2021 11:02:13 CET | Business Wire | Press release

Share
Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Selected by Product Innovation Brand biOrb

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that its SunLike Series natural spectrum LEDs, which implement light that closely matches the spectrum of sunlight, has been adopted by biOrb for its innovative new Vivariums.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005201/en/

biOrb Vivariums (from Oase) have created an innovative and original approach which allows reptile enthusiasts to recreate their own small biome. Recent research is showing that one of the most important aspects in recreating a natural habitat is the quality of the light used, after millions of years of evolution, full spectrum light is a major part of the animal's welfare, until now, this has been impossible to achieve. But now with Sunlike reptiles and plants are thriving and the hobbyist can see their world as nature intended, in all its vibrancy.

With SunLike Series natural spectrum LEDs, the fixtures are designed to bring out the natural colour tones of objects achieving a lower blue light peak, similar to the sunlight spectral curve, which enables the reduction of scattered reflection and glare and it also provides healthy and comfortable light, improving the environment for living and displaying colors and textures more accurately with CRI 97 and TM30 = 100.

There has been a significant increase in research activity on the relationship between light and human and animal bio-functions, including a recent scientific study focused on the effects of light spectrum on sleep quality, visual comfort, overall well-being, and daytime alertness; encompassing the interaction of both visual and non-visual light on humans, plants and animals. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.”

“Seoul Semiconductor’s SunLike Series natural spectrum LEDs have two beneficial effects in contrast to conventional LEDs for animals. There is the right amount of cyan 490nm wavelength to stimulate them during the day and there is no blue energy in the night to calm and prepare the animals to sleep like the real day/night cycle” said Oliver Schaefer Europe Executive Vice President of Seoul Semiconductor. “We have more and more customers interested in the SunLike technology as thanks to scientists we are discovering new applications every day” added him.

SunLike Series LEDs are an advanced technology that has achieved the highest level of eye safety certification from the International Commission on Illumination as a safe light source with no photo-biological risks.

Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combine the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” its original concept. The sun light spectrum is developed by the same company and can be reproduced by a white LED light source technology. TRI-R is a registered trademark by the Toshiba Materials Co., LTD.

About biOrb

Since 1999 biOrb has stood for innovation. Initially designing easy-to-own aquariums and more latterly, Terrariums and now Vivariums.

Today, biOrb is owned by German manufacturer OASE. The OASE name stands for spectacular fountains and “state of the art” equipment and services. Founded in 1949, OASE is now the market leader in the fountain technology industry. Our innovative products are designed for long life with maximized reliability as well as ease of maintenance and our support & service are the best in the industry. Headquartered in Germany, OASE understands the importance of a local presence to customers. We believe it is important to support our customers wherever they are located. With 13 subsidiaries in Europe, Asia and the US and a network of certified local partners we provide our customers fast, reliable, and efficient after Sales Services in their native language whenever and wherever they are needed.

About Seoul Semiconductor

Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye